Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
HER2 inhibitor
DRUG CLASS:
HER2 inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
trastuzumab (404)
afatinib (226)
lapatinib (106)
neratinib (102)
pyrotinib (77)
tucatinib (36)
trastuzumab-pkrb (24)
margetuximab (18)
poziotinib (17)
MCLA-128 (16)
KN026 (13)
mobocertinib (12)
trastuzumab-dttb (11)
ZW25 (10)
trastuzumab-anns (9)
trastuzumab-dkst (9)
trastuzumab-qyyp (9)
LZM-005 (8)
PRS-343 (8)
D3L-001 (7)
Zercepac (trastuzumab biosimilar) (7)
inetetamab (6)
ASLAN001 (6)
BDTX-189 (5)
AEE788 (4)
MT-5111 (4)
ORIC-114 (4)
TAS2940 (4)
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T (4)
MET306 (4)
pertuzumab/trastuzumab/hyaluronidase-zzxf (3)
DZD9008 (3)
trastuzumab-IFN-β mutein (3)
AST-301 (2)
Bay846 (2)
CT-0508 (2)
DF1001 (2)
ER121 (2)
Her-VAXX (2)
trastuzumab/hyaluronidase-oysk (2)
JBJ-08–178–01 (2)
SAR446309 (2)
BDC-1001 (2)
AB-201 (1)
ABL105 (1)
ACE1702 (1)
Hercease (trastuzumab biosimilar) (1)
BAY 2927088 (1)
BAY2701439 (1)
DZD1516 (1)
HERtiCAD (trastuzumab biosimilar) (1)
Hervelous (trastuzumab biosimilar) (1)
EG12014 (trastuzumab biosimilar) (1)
IAH0968 (1)
IMM2902 (1)
MP0274 (1)
SAR443216 (1)
TX05 (trastuzumab biosimilar) (1)
VRN101099 (1)
ZN-A-1041 (1)
S-222611 (1)
KD019 (1)
ADG138 (0)
ALT02 (trastuzumab biosimilar) (0)
trastuzumab biosimilar (AP062) (0)
B-Vaxx (0)
BAT1006 (0)
BAY2701438 (0)
BMS690514 (0)
CAM-H2 (0)
CAT-179 (0)
CUDC-101 (0)
DA 3111 (trastuzumab biosimilar) (0)
DS-2087b (0)
(0)
ELVN-002 (0)
ES2B-C001 (0)
ETBX-021 (0)
(0)
GB235 (0)
HER-2/neu peptide vaccine (0)
HER2 t-haNK (0)
HF158K1 (0)
HLX11 (pertuzumab biosimilar) (0)
HS-10376 (0)
Hervycta (trastuzumab biosimilar) (0)
ISB 1302 (0)
JIN-A04 (0)
JNJ-26483327 (0)
OST-HER2 (0)
MBS301 (0)
MM 111 (0)
MP412 (0)
MVA-BN-HER2 (0)
NVL-330 (0)
NeuCeptin (trastuzumab biosimilar) (0)
nelipepimut-S (0)
lapuleucel-T (0)
OS47701 (0)
QP34563457 (0)
ertumaxomab (0)
trastuzumab biosimilar (SIBP-01) (0)
SPH5030 (0)
SSGJ-705 (0)
(0)
Sym013 (0)
TAC100-HER2 (0)
TAK-285 (0)
TAS0728 (0)
TPIV100 (0)
(0)
TQB2930 (0)
glycooptimized trastuzumab-GEX (0)
TrastuRel (trastuzumab biosimilar) (0)
Undisclosed HER2Bi-armed ATC (0)
VM 206 (0)
AST1306 (0)
cipatinib (0)
dHER2+AS15 (0)
IBI315 (0)
KBP-5209 (0)
RG6194 (0)
AZD8931 (0)
trastuzumab biosimilar (0)
trastuzumab biosimilar (0)
trastuzumab (404)
afatinib (226)
lapatinib (106)
neratinib (102)
pyrotinib (77)
tucatinib (36)
trastuzumab-pkrb (24)
margetuximab (18)
poziotinib (17)
MCLA-128 (16)
KN026 (13)
mobocertinib (12)
trastuzumab-dttb (11)
ZW25 (10)
trastuzumab-anns (9)
trastuzumab-dkst (9)
trastuzumab-qyyp (9)
LZM-005 (8)
PRS-343 (8)
D3L-001 (7)
Zercepac (trastuzumab biosimilar) (7)
inetetamab (6)
ASLAN001 (6)
BDTX-189 (5)
AEE788 (4)
MT-5111 (4)
ORIC-114 (4)
TAS2940 (4)
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T (4)
MET306 (4)
pertuzumab/trastuzumab/hyaluronidase-zzxf (3)
DZD9008 (3)
trastuzumab-IFN-β mutein (3)
AST-301 (2)
Bay846 (2)
CT-0508 (2)
DF1001 (2)
ER121 (2)
Her-VAXX (2)
trastuzumab/hyaluronidase-oysk (2)
JBJ-08–178–01 (2)
SAR446309 (2)
BDC-1001 (2)
AB-201 (1)
ABL105 (1)
ACE1702 (1)
Hercease (trastuzumab biosimilar) (1)
BAY 2927088 (1)
BAY2701439 (1)
DZD1516 (1)
HERtiCAD (trastuzumab biosimilar) (1)
Hervelous (trastuzumab biosimilar) (1)
EG12014 (trastuzumab biosimilar) (1)
IAH0968 (1)
IMM2902 (1)
MP0274 (1)
SAR443216 (1)
TX05 (trastuzumab biosimilar) (1)
VRN101099 (1)
ZN-A-1041 (1)
S-222611 (1)
KD019 (1)
ADG138 (0)
ALT02 (trastuzumab biosimilar) (0)
trastuzumab biosimilar (AP062) (0)
B-Vaxx (0)
BAT1006 (0)
BAY2701438 (0)
BMS690514 (0)
CAM-H2 (0)
CAT-179 (0)
CUDC-101 (0)
DA 3111 (trastuzumab biosimilar) (0)
DS-2087b (0)
(0)
ELVN-002 (0)
ES2B-C001 (0)
ETBX-021 (0)
(0)
GB235 (0)
HER-2/neu peptide vaccine (0)
HER2 t-haNK (0)
HF158K1 (0)
HLX11 (pertuzumab biosimilar) (0)
HS-10376 (0)
Hervycta (trastuzumab biosimilar) (0)
ISB 1302 (0)
JIN-A04 (0)
JNJ-26483327 (0)
OST-HER2 (0)
MBS301 (0)
MM 111 (0)
MP412 (0)
MVA-BN-HER2 (0)
NVL-330 (0)
NeuCeptin (trastuzumab biosimilar) (0)
nelipepimut-S (0)
lapuleucel-T (0)
OS47701 (0)
QP34563457 (0)
ertumaxomab (0)
trastuzumab biosimilar (SIBP-01) (0)
SPH5030 (0)
SSGJ-705 (0)
(0)
Sym013 (0)
TAC100-HER2 (0)
TAK-285 (0)
TAS0728 (0)
TPIV100 (0)
(0)
TQB2930 (0)
glycooptimized trastuzumab-GEX (0)
TrastuRel (trastuzumab biosimilar) (0)
Undisclosed HER2Bi-armed ATC (0)
VM 206 (0)
AST1306 (0)
cipatinib (0)
dHER2+AS15 (0)
IBI315 (0)
KBP-5209 (0)
RG6194 (0)
AZD8931 (0)
trastuzumab biosimilar (0)
trastuzumab biosimilar (0)
›
Associations
(1162)
News
Trials
VERI cancer hierarchy
Reset Filters
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
pyrotinib + inetetamab
Sensitive: C3 – Early Trials
ESMO Asia 2023 - 6 days (New C3)
pyrotinib + inetetamab
Sensitive
:
C3
ESMO Asia 2023 - 6d
pyrotinib + inetetamab
Sensitive: C3 – Early Trials
ESMO Asia 2023 - 6 days
pyrotinib + inetetamab
Sensitive
:
C3
ESMO Asia 2023 - 6 days - (New C3)
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
camrelizumab + pyrotinib
Sensitive: C3 – Early Trials
EClinicalMedicine - 1 week (New C3)
camrelizumab + pyrotinib
Sensitive
:
C3
EClinicalMedicine - 1wk
camrelizumab + pyrotinib
Sensitive: C3 – Early Trials
EClinicalMedicine - 1 week
camrelizumab + pyrotinib
Sensitive
:
C3
EClinicalMedicine - 1 week - (New C3)
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
camrelizumab + pyrotinib
Sensitive: C3 – Early Trials
EClinicalMedicine - 1 week (New C3)
camrelizumab + pyrotinib
Sensitive
:
C3
EClinicalMedicine - 1wk
camrelizumab + pyrotinib
Sensitive: C3 – Early Trials
EClinicalMedicine - 1 week
camrelizumab + pyrotinib
Sensitive
:
C3
EClinicalMedicine - 1 week - (New C3)
EGFR L833V + EGFR H835L
Non Small Cell Lung Cancer
EGFR L833V + EGFR H835L
Non Small Cell Lung Cancer
afatinib + anlotinib
Sensitive: C4 – Case Studies
Zhongguo Fei Ai Za Zhi - 1 week (New C4)
afatinib + anlotinib
Sensitive
:
C4
Zhongguo Fei Ai Za Zhi - 1wk
afatinib + anlotinib
Sensitive: C4 – Case Studies
Zhongguo Fei Ai Za Zhi - 1 week
afatinib + anlotinib
Sensitive
:
C4
Zhongguo Fei Ai Za Zhi - 1 week - (New C4)
RAS wild-type + HER-2 positive
Colorectal Cancer
RAS wild-type + HER-2 positive
Colorectal Cancer
trastuzumab + pyrotinib
Sensitive: C3 – Early Trials
Clin Colorectal Cancer - 2 weeks (New C3)
trastuzumab + pyrotinib
Sensitive
:
C3
Clin Colorectal Cancer - 2wk
trastuzumab + pyrotinib
Sensitive: C3 – Early Trials
Clin Colorectal Cancer - 2 weeks
trastuzumab + pyrotinib
Sensitive
:
C3
Clin Colorectal Cancer - 2 weeks - (New C3)
ER positive
HER2 Negative Breast Cancer
ER positive
HER2 Negative Breast Cancer
HER2 inhibitor
Sensitive: C3 – Early Trials
Hum Pathol - 2 weeks (New C3)
HER2 inhibitor
Sensitive
:
C3
Hum Pathol - 2wk
HER2 inhibitor
Sensitive: C3 – Early Trials
Hum Pathol - 2 weeks
HER2 inhibitor
Sensitive
:
C3
Hum Pathol - 2 weeks - (New C3)
ER negative
HER2 Positive Breast Cancer
ER negative
HER2 Positive Breast Cancer
HER2 inhibitor
Sensitive: C3 – Early Trials
Hum Pathol - 2 weeks (New C3)
HER2 inhibitor
Sensitive
:
C3
Hum Pathol - 2wk
HER2 inhibitor
Sensitive: C3 – Early Trials
Hum Pathol - 2 weeks
HER2 inhibitor
Sensitive
:
C3
Hum Pathol - 2 weeks - (New C3)
RAS wild-type + HER-2 positive
Colorectal Cancer
RAS wild-type + HER-2 positive
Colorectal Cancer
pyrotinib
Sensitive: C3 – Early Trials
Clin Colorectal Cancer - 2 weeks (New C3)
pyrotinib
Sensitive
:
C3
Clin Colorectal Cancer - 2wk
pyrotinib
Sensitive: C3 – Early Trials
Clin Colorectal Cancer - 2 weeks
pyrotinib
Sensitive
:
C3
Clin Colorectal Cancer - 2 weeks - (New C3)
HER-2 positive + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
HER-2 positive + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
FDA - 3 weeks (New A1)
pembrolizumab + trastuzumab
Sensitive
:
A1
FDA - 3wk
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
FDA - 3 weeks
pembrolizumab + trastuzumab
Sensitive
:
A1
FDA - 3 weeks - (New A1)
HER-2 positive + PD-L1 expression
Gastric Cancer
HER-2 positive + PD-L1 expression
Gastric Cancer
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
FDA - 3 weeks (New A1)
pembrolizumab + trastuzumab
Sensitive
:
A1
FDA - 3wk
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
FDA - 3 weeks
pembrolizumab + trastuzumab
Sensitive
:
A1
FDA - 3 weeks - (New A1)
HER-2 positive + TP53 mutation
Biliary Tract Cancer
HER-2 positive + TP53 mutation
Biliary Tract Cancer
trastuzumab
Resistant: C3 – Early Trials
J Clin Oncol - 3 weeks (New C3)
trastuzumab
Resistant
:
C3
J Clin Oncol - 3wk
trastuzumab
Resistant: C3 – Early Trials
J Clin Oncol - 3 weeks
trastuzumab
Resistant
:
C3
J Clin Oncol - 3 weeks - (New C3)
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
HER2 inhibitor + Erythropoiesis stimulating agent
Sensitive: C3 – Early Trials
Breast Cancer Res Treat - 3 weeks (New C3)
HER2 inhibitor + Erythropoiesis stimulating agent
Sensitive
:
C3
Breast Cancer Res Treat - 3wk
HER2 inhibitor + Erythropoiesis stimulating agent
Sensitive: C3 – Early Trials
Breast Cancer Res Treat - 3 weeks
HER2 inhibitor + Erythropoiesis stimulating agent
Sensitive
:
C3
Breast Cancer Res Treat - 3 weeks - (New C3)
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
bevacizumab + mobocertinib
Sensitive: C4 – Case Studies
JTO Clin Res Rep - 3 weeks (New C4)
bevacizumab + mobocertinib
Sensitive
:
C4
JTO Clin Res Rep - 3wk
bevacizumab + mobocertinib
Sensitive: C4 – Case Studies
JTO Clin Res Rep - 3 weeks
bevacizumab + mobocertinib
Sensitive
:
C4
JTO Clin Res Rep - 3 weeks - (New C4)
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + pyrotinib
Sensitive: B - Late Trials
BMJ - 4 weeks (New B)
trastuzumab + pyrotinib
Sensitive
:
B
BMJ - 4wk
trastuzumab + pyrotinib
Sensitive: B - Late Trials
BMJ - 4 weeks
trastuzumab + pyrotinib
Sensitive
:
B
BMJ - 4 weeks - (New B)
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T
Sensitive: C3 – Early Trials
SITC 2023 - 4 weeks (New C3)
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T
Sensitive
:
C3
SITC 2023 - 4wk
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T
Sensitive: C3 – Early Trials
SITC 2023 - 4 weeks
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T
Sensitive
:
C3
SITC 2023 - 4 weeks - (New C3)
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
trastuzumab + abemaciclib
Sensitive: C3 – Early Trials
Clin Cancer Res - 4 weeks (New C3)
trastuzumab + abemaciclib
Sensitive
:
C3
Clin Cancer Res - 4wk
trastuzumab + abemaciclib
Sensitive: C3 – Early Trials
Clin Cancer Res - 4 weeks
trastuzumab + abemaciclib
Sensitive
:
C3
Clin Cancer Res - 4 weeks - (New C3)
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T
Sensitive: C3 – Early Trials
SITC 2023 - 4 weeks (New C3)
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T
Sensitive
:
C3
SITC 2023 - 4wk
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T
Sensitive: C3 – Early Trials
SITC 2023 - 4 weeks
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T
Sensitive
:
C3
SITC 2023 - 4 weeks - (New C3)
High PLR
HER2 Positive Breast Cancer
High PLR
HER2 Positive Breast Cancer
pyrotinib
Resistant: C3 – Early Trials
Transl Cancer Res - 4 weeks (New C3)
pyrotinib
Resistant
:
C3
Transl Cancer Res - 4wk
pyrotinib
Resistant: C3 – Early Trials
Transl Cancer Res - 4 weeks
pyrotinib
Resistant
:
C3
Transl Cancer Res - 4 weeks - (New C3)
High MLR
HER2 Positive Breast Cancer
High MLR
HER2 Positive Breast Cancer
pyrotinib
Resistant: C3 – Early Trials
Transl Cancer Res - 4 weeks (New C3)
pyrotinib
Resistant
:
C3
Transl Cancer Res - 4wk
pyrotinib
Resistant: C3 – Early Trials
Transl Cancer Res - 4 weeks
pyrotinib
Resistant
:
C3
Transl Cancer Res - 4 weeks - (New C3)
High NLR
HER2 Positive Breast Cancer
High NLR
HER2 Positive Breast Cancer
pyrotinib
Resistant: C3 – Early Trials
Transl Cancer Res - 4 weeks (New C3)
pyrotinib
Resistant
:
C3
Transl Cancer Res - 4wk
pyrotinib
Resistant: C3 – Early Trials
Transl Cancer Res - 4 weeks
pyrotinib
Resistant
:
C3
Transl Cancer Res - 4 weeks - (New C3)
Low PLR
HER2 Positive Breast Cancer
Low PLR
HER2 Positive Breast Cancer
pyrotinib
Sensitive: C3 – Early Trials
Transl Cancer Res - 4 weeks (New C3)
pyrotinib
Sensitive
:
C3
Transl Cancer Res - 4wk
pyrotinib
Sensitive: C3 – Early Trials
Transl Cancer Res - 4 weeks
pyrotinib
Sensitive
:
C3
Transl Cancer Res - 4 weeks - (New C3)
HER-2 expression
Gastric Cancer
HER-2 expression
Gastric Cancer
ado-trastuzumab emtansine + AST-301
Sensitive: D – Preclinical
SITC 2023 - 4 weeks (New D)
ado-trastuzumab emtansine + AST-301
Sensitive
:
D
SITC 2023 - 4wk
ado-trastuzumab emtansine + AST-301
Sensitive: D – Preclinical
SITC 2023 - 4 weeks
ado-trastuzumab emtansine + AST-301
Sensitive
:
D
SITC 2023 - 4 weeks - (New D)
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
afatinib
Sensitive: A1 - Approval
afatinib
Sensitive
:
A1
afatinib
Sensitive: A1 - Approval
afatinib
Sensitive
:
A1
EGFR L858R
Non Small Cell Lung Cancer
EGFR L858R
Non Small Cell Lung Cancer
afatinib
Sensitive: A1 - Approval
afatinib
Sensitive
:
A1
afatinib
Sensitive: A1 - Approval
afatinib
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + tucatinib
Sensitive: A1 - Approval
trastuzumab + tucatinib
Sensitive
:
A1
trastuzumab + tucatinib
Sensitive: A1 - Approval
trastuzumab + tucatinib
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive: A1 - Approval
trastuzumab + pertuzumab
Sensitive
:
A1
trastuzumab + pertuzumab
Sensitive: A1 - Approval
trastuzumab + pertuzumab
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
margetuximab
Sensitive: A1 - Approval
margetuximab
Sensitive
:
A1
margetuximab
Sensitive: A1 - Approval
margetuximab
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
EGFR mutation
Non Small Cell Lung Cancer
EGFR mutation
Non Small Cell Lung Cancer
afatinib
Sensitive: A1 - Approval
afatinib
Sensitive
:
A1
afatinib
Sensitive: A1 - Approval
afatinib
Sensitive
:
A1
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
mobocertinib
Sensitive: A1 - Approval
mobocertinib
Sensitive
:
A1
mobocertinib
Sensitive: A1 - Approval
mobocertinib
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
pembrolizumab + trastuzumab
Sensitive
:
A1
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
pembrolizumab + trastuzumab
Sensitive
:
A1
HR positive
HER2 Positive Breast Cancer
HR positive
HER2 Positive Breast Cancer
neratinib
Sensitive: A1 - Approval
neratinib
Sensitive
:
A1
neratinib
Sensitive: A1 - Approval
neratinib
Sensitive
:
A1
HER-2 overexpression
Gastric Cancer
HER-2 overexpression
Gastric Cancer
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
pertuzumab/trastuzumab/hyaluronidase-zzxf
Sensitive: A1 - Approval
pertuzumab / trastuzumab / hyaluronidase-zzxf
Sensitive
:
A1
pertuzumab/trastuzumab/hyaluronidase-zzxf
Sensitive: A1 - Approval
pertuzumab / trastuzumab / hyaluronidase-zzxf
Sensitive
:
A1
HER-2 amplification
Hormone Receptor Positive Breast Cancer
HER-2 amplification
Hormone Receptor Positive Breast Cancer
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
HER-2 amplification
HER2 Positive Breast Cancer
HER-2 amplification
HER2 Positive Breast Cancer
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
HER-2 overexpression
HER2 Positive Breast Cancer
HER-2 overexpression
HER2 Positive Breast Cancer
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
HER-2 overexpression
Gastric Cancer
HER-2 overexpression
Gastric Cancer
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
HER-2 amplification
Hormone Receptor Positive Breast Cancer
HER-2 amplification
Hormone Receptor Positive Breast Cancer
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
HER-2 amplification
HER2 Positive Breast Cancer
HER-2 amplification
HER2 Positive Breast Cancer
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
HER-2 overexpression
HER2 Positive Breast Cancer
HER-2 overexpression
HER2 Positive Breast Cancer
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
HER-2 overexpression
Gastric Cancer
HER-2 overexpression
Gastric Cancer
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
HER-2 amplification
Hormone Receptor Positive Breast Cancer
HER-2 amplification
Hormone Receptor Positive Breast Cancer
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
HER-2 amplification
HER2 Positive Breast Cancer
HER-2 amplification
HER2 Positive Breast Cancer
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
HER-2 overexpression
HER2 Positive Breast Cancer
HER-2 overexpression
HER2 Positive Breast Cancer
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
HER-2 overexpression
Gastric Cancer
HER-2 overexpression
Gastric Cancer
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
HER-2 amplification
Hormone Receptor Positive Breast Cancer
HER-2 amplification
Hormone Receptor Positive Breast Cancer
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login